Navigation Links
DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program

'Room Temp' Technology Builds on Consumer Appeal and Tactical Importance of

Needle-less Vaccinations

IRVING, Texas, Dec. 10 /PRNewswire-FirstCall/ -- An experimental drug delivery technology from the DelSite Biotechnologies subsidiary of Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) may help cut significant waste from the federal pediatric vaccine program, while greatly expanding the use of needle-less vaccines here and abroad.

The Associated Press last week reported that Lance E. Rodewald, MD, director of the Immunization Services division at the Centers for Disease Control and Prevention, said improper refrigeration is the single biggest problem causing waste in the $2-billion-a-year federal Vaccines for Children Program (VFC).

The new vaccine technology from Texas-based DelSite is the first of its class to eliminate the need for refrigerated storage. The DelSite technology formulates vaccines in a fine powder that may be stored and shipped at room temperature. The vaccine product may be administered nasally in a super-fine powder mist, or it may also be reconstituted into liquid form for conventional injections.

Once considered to be a marginal product, nasal versions of flu vaccines are gaining popularity, especially among parents of young children and with elderly people -- two age groups that tend to be skittish about needles. AstraZeneca, the makers of FluMist(R), the only currently approved nasal flu vaccine, expects higher US sales this flu season due to a switch from frozen to refrigerated storage and a just revised FDA label that now allows use in children under five. Last Friday, AstraZeneca announced plans to file for approval for FluMist in Europe and to accelerate its launch in the rest of the world.

Compared to FluMist, which is made of a live vaccine antigen in a liquid formulation, DelSite's nasal powder technology differs in several potentially important ways:

* DelSite-enhanced powder vaccines require no refrigerated shipping or storage.

* DelSite-enhanced powder vaccines make use of inactivated vaccine antigen and provide both nasal and systemic immunization.

* The composition of DelSite-enhanced vaccines confers adjuvant-like properties, boosting immunostimulation and potentially enabling lower dosing.

DelSite's nasal powder, which is expected to enter human clinical trials for effectiveness against flu early next year, is based on a chemically and functionally distinct high-molecular-weight ionic polysaccharide designed for in situ gelling. The polymer allows dry powder to change into gel particles upon contact with liquids in the nasal cavity. The in-situ gel provides sustained antigen release and prolonged nasal residence, thereby increasing exposure to the antigen that results in increased immune response.

There is a significant unmet global health need for influenza vaccines. All current influenza vaccines are liquid formulations that have a limited shelf life, require refrigeration for storage and distribution and, with the exception of one live vaccine product, are administered by injection.

DelSite's nasal powder influenza vaccine holds distinct advantages over current flu vaccines by providing long-term stability at room temperature, shipping and distribution with no need for refrigeration, and administration without a needle. In addition, the vaccine is preservative-free and induces both mucosal and systemic responses. These attributes make DelSite's nasal powder influenza vaccine particularly well suited for pandemic preparedness when such products may need to be stockpiled for extended periods of time and rapidly distributed and self administered under emergency conditions.

Once DelSite's nasal dry powder technology has been successfully developed for the influenza vaccine, these same advantages may also prove useful in formulating other biodefense products and a wide range of other vaccines to improve their storage and distribution, administration, and effectiveness.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology which is designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit

About DelSite

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc., is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institute of Health) under the Department of Health and Human Services.


Carrington Laboratories, Inc.

Carlton Turner, Ph.D., +1-972-518-1300

SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
2. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
3. Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. Novel Technology Breaks Through Cancer Pain
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Advanced Cell Technology Announces Proposed Financing
8. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... the Company has been dismissed by the court.  ... stated, "As we suspected, this case was brought by ...
(Date:10/12/2015)... , Oct. 12, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... company engaged in developing and commercializing novel treatments in ... of Dennis Turpin , the Company,s former Senior ... close its Quebec City office.  ... and Chief Executive Officer of the Company commented, "After ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl ... has joined the firm as a Premier Expert consultant. NDA Partners Premier ... bring extraordinary value to the company's clients. Premier Experts collaborate to design ...
(Date:10/10/2015)... 10. Oktober, 2015 Am 8. Oktober ... Demokratischen Partei für Kalifornien) ihre Würdigung der International ... in die Aufzeichnungen des Kongresses eintragen lassen. Die ... Association (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre ... des Bewusstseins über Plasmaspenden weltweit , Würdigung ...
Breaking Biology Technology:
(Date:9/28/2015)... FRANCISCO , September 28, 2015 ... is expected to reach USD 12.03 billion by 2020, ... 2020. Technological advancements such as Backside Illumination (BSI) technique ... growth over the forecast period.      (Logo: ... back of the chip to reduce loss and, thus, ...
(Date:9/26/2015)...  Results of a TactioRPM pilot project in ... the Stanford Medicine X Conference. In a presentation ... Health Devices and Pharmacogenomics", Roger Simard , ... how senior patients equipped with connected health devices ... the TactioRPM remote patient monitoring platform were empowered ...
(Date:9/10/2015)... -- This report provides detailed descriptions of the sensor ... sensor types that will dominate in the future. Many ... wearable technology hype curve in the last five years ... with all of them is the prominence of sensor ... functions. Sensors collect data about the physical and chemical ...
Breaking Biology News(10 mins):